Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen. Issue 10 (10th July 2019)

• Record Type: Journal Article
• Authors: Kusakabe, Atsunori; Kurosaki, Masayuki; Itakura, Jun; Joko, Kouji; Akahane, Takehiro; Tsuji, Keiji; Kobashi, Haruhiko; Sohda, Tetsuro; Kimura, Hiroyuki; Narita, Ryouichi; Furuta, Koichirou; Izumi, Namiki
• Is Part Of: Hepatology research. Volume 49:Issue 10(2019)
• Page Start: 1121
• Page End: 1126
• Publication Date: 2019-07-10
• Subjects: chronic hepatitis C -- glecaprevir -- pibrentasvir -- retreatment; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.13387
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract : Aim: Rescue therapy for patients with genotype 2 (GT2) chronic hepatitis C who failed prior sofosbuvir (SOF) plus ribavirin (RBV) awaits establishment. This study aims to investigate the efficacy and safety of the fixed‐dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) (GLE/PIB) for patients with GT2 chronic hepatitis C. Methods: In this nationwide observational study undertaken by the Japanese Red Cross Liver Study Group, 28 GT2 patients with prior failure of SOF + RBV were retreated with GLE/PIB for 12 weeks. We evaluated the rate of sustained virologic response (SVR) and adverse events. Results: After 4 weeks of therapy, serum hepatitis C virus RNA was below the limit of quantification in all patients. The SVR after 4 and 12 weeks of the end of treatment was validated in 100% (28/28) and 100% (28/28), respectively. The adverse events comprised pruritus (eight patients), fatigue (four patients), and appetite loss (four patients), all of which were mild in severity. Conclusions: This study establishes the efficacy of GLE/PIB as retreatment in Japanese patients with GT2 chronic hepatitis C not responding to SOF + RBV.